Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus amurubicin (AMR).
Small Cell Lung Cancer Extensive Stage
DRUG: Pembrolizumab plus amurubicin
Overall response rate, Overall response rate will be assessed using RECIST ver1.1 by investigators, Imaging will be performed every 6 weeks through study completion, an average of 6 months
Open, uncontrolled, multi-center, phase II study.